MAFF inhibits angiogenesis in non-small cell lung cancer by suppressing YAP1 nuclear translocation
PeerJ · 2025
DOI: 10.7717/peerj.20395 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, 2025. Verfasst von Yao Ding und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Youjiang Medical University for Nationalities, Baise, Guangxi, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Adaptor Proteins, Signal Transducing, Neovascularization, Pathologic. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Guangxi Natural Science Foundation Project, Guangxi Zhuang Autonomous Region Health and Family Planning Commission.
Abstract (Originalsprache)
Objective
To investigate the roles of MAFF and Yes-associated protein 1 (YAP1) in regulating angiogenesis in non-small cell lung cancer (NSCLC) and to explore the mechanism through which MAFF inhibits angiogenesis by suppressing YAP1 nuclear translocation.
Methods
Bioinformatics analysis was used to assess MAFF expression and its associated regulatory pathways. Clinical samples from NSCLC patients were analyzed by immunohistochemistry (IHC) to evaluate the correlation between MAFF expression and microvessel density (MVD). Cellular experiments were conducted to examine the effects of MAFF overexpression on proliferation, migration, and angiogenesis. Western blot (WB) and immunofluorescence (IF) analyses were performed to assess the expression of YAP1, vascular endothelial growth factor (VEGF), and connective tissue growth factor (CTGF). Tumor growth suppression was evaluated using nude mouse xenograft models.
Results
MAFF was significantly downregulated in NSCLC tissues and correlated with advanced T stage and higher MVD. Overexpression of MAFF inhibited NSCLC cell proliferation, migration, and angiogenesis, and downregulated the expression of YAP1, VEGF, and CTGF. IF confirmed that MAFF suppressed nuclear translocation of YAP1. In vivo , MAFF overexpression reduced tumor volume and weight, which was accompanied by inhibition of the YAP1 signaling pathway.
Conclusion
MAFF suppresses angiogenesis in NSCLC by blocking YAP1 nuclear translocation and downregulating VEGF and CTGF, highlighting its potential as a therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medical Sciences, Youjiang Medical University for Nationalities, Baise, Guangxi, China.
- Department of Pathology, Jiangsu College of Nursing, Huaian, Jiangsu, China.
- Scientific Experiment Center, Baise People's Hospital, Baise, Guangxi, China.
ORCID-Profile: Yi Zeng
Förderung
- Guangxi Natural Science Foundation Project
- Guangxi Zhuang Autonomous Region Health and Family Planning Commission
Zitieren
APA
Ding, Y., Wang, S., Hu, R., Cao, Z., Zou, Y., Yang, W. L., Ji, W., Liu, L., Xiao, N., Li, X. L., & Zeng, Y. (2025). MAFF inhibits angiogenesis in non-small cell lung cancer by suppressing YAP1 nuclear translocation. PeerJ. https://doi.org/10.7717/peerj.20395
Vancouver
Ding Y, Wang S, Hu R, Cao Z, Zou Y, Yang WL, et al. MAFF inhibits angiogenesis in non-small cell lung cancer by suppressing YAP1 nuclear translocation. PeerJ. 2025. doi:10.7717/peerj.20395
BibTeX
@article{Ding2025,
author = {Ding, Yao and Wang, Shizi and Hu, Rui and Cao, ZiYi and Zou, Yuting and Yang, Wei-Ling and Ji, Weihang and Liu, Lin and Xiao, Na and Li, Xiao Lei and Zeng, Yi},
title = {MAFF inhibits angiogenesis in non-small cell lung cancer by suppressing YAP1 nuclear translocation},
journal = {PeerJ},
year = {2025},
doi = {10.7717/peerj.20395}
}
EUVIMED